When combined with chemotherapeutic agents for HER2-positive breast cancer (neratinib or trastuzumab), HER2-TRIM-ing enhanced drug efficacy and the levels of downstream molecules, p-ERK and p-AKT further decreased, validating the therapeutic potential of TRIM-ing technology. This evidence concerns the gene AKT1 and breast cancer.